Tenaya Therapeutics names Eric Hyllengren as new CFO effective July 13, 2026

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced on June 29, 2026 the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026.¹ Beginning on that date, Hyllengren will also serve as the company's Principal Financial Officer and Principal Accounting Officer.¹

In his new role, Hyllengren will oversee financial strategy, capital allocation, investor relations and corporate development.¹

Prior to joining Tenaya, Hyllengren, age 51, served as Chief Financial Officer at Zura Bio Ltd. from July 2025 until April 2026.¹ Before that, he spent seven years at Atara Biotherapeutics, Inc., most recently serving as Chief Financial Officer and Chief Operating Officer, from April 2023 and October 2024 respectively, until April 2025, after having been Atara's Vice President of Finance and Investor Relations from August 2018 until April 2023.¹ Earlier, he held roles of increasing responsibility across finance, investor relations, and business development at Amgen Inc., where he was most recently Executive Director of Business Development and Head of Alliance Management from 2017 to 2018.¹

Under his offer letter dated June 18, 2026, Hyllengren will receive an annual base salary of $490,000 and will be eligible for a target annual bonus equal to 40% of his base salary.¹ He is also set to receive, subject to board approval, an option to purchase 1,650,000 shares of common stock under the company's 2024 Inducement Equity Incentive Plan, with an exercise price at fair market value and a 10-year term.¹

Separately, Tenaya disclosed that Tomohiro Higa, the company's Senior Vice President, Finance, will cease serving as acting interim Principal Accounting Officer effective immediately prior to Hyllengren's start date.¹ The filing states Higa's retirement, set for the third quarter of 2026, is unrelated to Hyllengren's hire, and Higa will remain with Tenaya as a consultant to help transition the finance and accounting function.¹